Oncology Archives - Page 11 of 20

GPCR-Membrane Protein Platform

WuXi AppTec provides a comprehensive platform of advanced biophysical assays and structural biology services to accelerate lead optimization efforts focused...

Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment

SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by...

Progress and Challenges in Tumor Vaccine Development

Introduction: Cancer is a major public health concern, and this disease is a leading cause of death worldwide. There are...

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an...

Osimertinib-Resistant Cell Lines and Models

Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug. ...

Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently...

On-target, off-tumor toxicity is a specific type of toxic side effect that limits the anticancer applicability of chimeric antigen receptor...

OncoWuXi Express: Large-scale Cell Panel Screening Platform for Integrated Pharmacogenomics and Bioinformatics Research

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as...

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors

The KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinomas (PDAC), making this an important drug...

Anti-Tumor Nucleic Acid Drug Discovery Platform

Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects. To address these challenges, WuXi...

Knowledge Library